Anthera Pharmaceutical ... -80%
This is biotech "at its best".
An expert review board gave this drug an approval of passing, with a shelf offering of about $100 millions.
And now ... Sollpura has just failed to achieve the desired results in a Phase 3 clinical study ...
Luckily, I closed one trade with a win for this stock.
Conclusion: Stay away from small biotech firms!
An expert review board gave this drug an approval of passing, with a shelf offering of about $100 millions.
And now ... Sollpura has just failed to achieve the desired results in a Phase 3 clinical study ...
Luckily, I closed one trade with a win for this stock.
Conclusion: Stay away from small biotech firms!
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。